The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...